心脏肌钙蛋白在心脏骤停后诊疗中的诊断与预后价值
该回顾性单中心注册研究纳入145例心脏骤停后恢复自主循环且接受连续心肌肌钙蛋白T(cTnT)检测、超声心动图和病因专家裁定的患者,评估初始和峰值cTnT对缺血性病因、左室收缩功能障碍(LVSD)和出院生存的判别能力。结果显示,全部患者初始cTnT均高于0.01 ng/mL临床界值;即使将阈值提高至10倍、100倍和1000倍,初始cTnT对缺血性病因的AUROC仅为0.57、0.56和0.56,峰值cTnT为0.55、0.61和0.62。对LVSD和出院生存的预测效能同样不佳(所有AUROC<0.6)。作者认为,cTnT不足以指导临床决策或预测患者结局,常规检测应重新评估。
要点
- 全部145例患者初始cTnT均高于0.01 ng/mL临床界值,该检测在心脏骤停后普遍阳性,鉴别缺血性病因的价值有限。
- 即使阈值提高至10倍、100倍、1000倍,初始cTnT对缺血性病因的AUROC仅为0.57、0.56、0.56,峰值cTnT为0.55、0.61、0.62。
- 初始和峰值cTnT对LVSD的预测效能同样不佳至中等(初始AUROC 0.60、0.62、0.55;峰值0.57、0.61、0.62)。
- cTnT对出院生存的预测效能差,所有AUROC均<0.6。
- 作者认为,在当前及数倍升高阈值下,cTnT均不足以指导临床决策或预测患者结局,常规心脏骤停后检测应重新评估。
适用人群与场景
- 心脏骤停后恢复自主循环、并接受了连续心肌肌钙蛋白T检测、超声心动图和病因专家裁定的成人患者。
- 单中心连续纳入的145例患者,平均年龄61±14岁,71%为男性。
诊断标准与关键阈值
- cTnT临床界值为0.01 ng/mL;研究还评估了10倍、100倍和1000倍升高阈值下的判别效能。
研究设计与关键结果
- 回顾性单中心注册研究,纳入145例心脏骤停后恢复自主循环的患者,平均年龄61±14岁,71%为男性。
- 19%的患者病因为缺血性,68%存在心脏骤停后LVSD,55%存活至出院。
- 全部患者初始cTnT均高于0.01 ng/mL临床界值。
- 对缺血性病因:初始cTnT在10倍、100倍、1000倍阈值下AUROC分别为0.57、0.56、0.56;峰值cTnT分别为0.55、0.61、0.62。
- 对LVSD:初始cTnT在10倍、100倍、1000倍阈值下AUROC分别为0.60、0.62、0.55;峰值cTnT分别为0.57、0.61、0.62。
- 对出院生存:所有AUROC均<0.6。
证据类型、等级与局限
- 证据类型:回顾性单中心注册研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在当前及数倍升高阈值下,cTnT均不足以指导临床决策或预测患者结局。
- 作者认为,心脏骤停后常规cTnT检测应重新评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac troponin is routinely tested in the post-cardiac arrest setting, but its utility in identifying ischaemic aetiology and predicting left ventricular systolic dysfunction (LVSD) and survival is not known.
METHODS: In a retrospective single center registry, we identified 145 consecutive patients who had achieved return of spontaneous circulation after cardiac arrest and had undergone serial cardiac troponin T (cTnT) testing, echocardiogram, and expert adjudication of aetiology. Initial and peak cTnT were evaluated for assessing ischaemic aetiology, LVSD, and survival to discharge using area under the receiver operating characteristic curve (AUROC).
RESULTS: Mean age was 61 ± 14 years and 71% were men. Of the 145 arrests, 19% had an ischaemic aetiology, 68% had LVSD post-arrest, and 55% survived to discharge. All patients had a positive initial cTnT at 0.01 ng/mL (clinical cut-off). Even at higher cut-offs of 10×, 100× and 1000×, initial cTnT performed poorly (AUROC 0.57, 0.56, and 0.56) and peak cTnT performed modestly (AUROC 0.55, 0.61, and 0.62) as diagnostic tests for ischaemic aetiology. Similarly, even at higher cut-offs, initial (AUROC 0.60, 0.62, 0.55) and peak (AUROC 0.57, 0.61, and 0.62) cTnT performed poorly to modestly at predicting LVSD. The test performed poorly for predicting survival to discharge (AUROC for all <0.6).
CONCLUSIONS: At both current and several-fold higher thresholds, cTnT does not perform sufficiently well to guide clinical decision-making or predict patient outcomes. Routine post-cardiac arrest testing of cTnT should be reevaluated.
参考来源
- Agusala V, Khera R, Cheeran D, et al. Diagnostic and prognostic utility of cardiac troponin in post-cardiac arrest care. Resuscitation. 2019. PMID: 31201884. doi:10.1016/j.resuscitation.2019.06.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。